An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women



Status:Completed
Conditions:Osteoporosis, Postmenopausal Syndrome
Therapuetic Areas:Endocrinology, Rheumatology
Healthy:No
Age Range:55 - 90
Updated:11/10/2018
Start Date:January 31, 2013
End Date:May 14, 2015

Use our guide to learn which trials are right for you!

An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With Romosozumab in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy

The primary objective of the study was to evaluate the effect of 12 months of treatment with
romosozumab compared with teriparatide on total hip bone mineral density (BMD) in
postmenopausal women with osteoporosis who were previously treated with bisphosphonate
therapy.


Inclusion Criteria:

- Postmenopausal women, aged ≥ 55 to ≤ 90.

- Received oral bisphosphonate therapy for at least 3 years immediately prior to
screening

- BMD T-score ≤ -2.50 at the lumbar spine, total hip or femoral neck

- History of nonvertebral fracture after age 50, or vertebral fracture.

Exclusion Criteria:

- Use of other agents affecting bone metabolism including Strontium ranelate, fluoride
(for osteoporosis), odanacatib (MK-0822) or any other cathepsin K inhibitor, IV
bisphosphonates, denosumab, teriparatide (TPTD) or any parathyroid hormone (PTH)
analogs, Systemic oral or transdermal estrogen, selective estrogen receptor modulators
(SERMs), activated vitamin D3, vitamin K2, calcitonin, tibolone, cinacalcet, systemic
glucocorticosteroids:

- History of metabolic or bone disease (except osteoporosis) that may interfere with the
interpretation of study results, such as sclerosteosis, Paget's disease, rheumatoid
arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing
spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome.

- Vitamin D insufficiency, defined as 25 (OH) vitamin D levels < 20 ng/mL, as determined
by the central laboratory.

- Current hyper- or hypocalcemia

- Current, uncontrolled hyper- or hypothyroidism
We found this trial at
6
sites
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
Ciudad Autónoma de Buenos Aires, Buenos Aires
?
mi
from
Ciudad Autónoma de Buenos Aires,
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Gainesville, GA
Click here to add this to my saved trials